» Articles » PMID: 40076652

Pro-Apoptotic Effects of Anandamide in Human Gastric Cancer Cells Are Mediated by AKT and ERK Signaling Pathways

Abstract

Gastric cancer is one of the most common forms of cancer worldwide. A growing number of studies have addressed the anti-proliferative effects of cannabinoids on several tumor cells. The molecular mechanisms underlying the anti-proliferative effects of the endogenous cannabinoid anandamide (AEA) on gastric tumor cell lines have yet to be characterized. Here, we investigated the anti-proliferative mechanisms elicited by AEA on the AGS human gastric cancer cell line employing an Oncoprint database, Western blotting, and immunofluorescence. We observed that AEA (5 µM) inhibited phosphorylated AKT's expression level. This point is relevant because AKT is mutated in AGS cells, according to Oncoprint. In addition, AEA induced the up-regulation of phosphorylated ERK and, in turn, inhibited Bcl-2 expression and activated pro-apoptotic signals induced by pro-apoptotic Bax and Bak, which resulted in caspase-3 activation. The effect of anandamide on phosphorylated AKT was dependent on cannabinoid receptor 2 activation (CB2R) as revealed by the selective inverse agonist JTE-907, which reverted the anandamide-induced expression in the phosphorylated AKT/total AKT ratio. In contrast, changes in phosphorylated ERK evoked an increase in pro-apoptotic pathways that culminated in cell death by caspase-3 activation. These results indicate that the endogenous cannabinoid anandamide in gastric cancer cells increases caspase-3 activity via mitochondrial pro-apoptotic Bax/Bak proteins and decreases viability through CB2R via AKT down-regulation's trophic mechanisms. These effects constitute a promising tool for the design of gastric cancer therapies.

References
1.
Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

2.
Letai A, Bassik M, Walensky L, Sorcinelli M, Weiler S, Korsmeyer S . Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002; 2(3):183-92. DOI: 10.1016/s1535-6108(02)00127-7. View

3.
Laezza C, Pagano C, Navarra G, Pastorino O, Proto M, Fiore D . The Endocannabinoid System: A Target for Cancer Treatment. Int J Mol Sci. 2020; 21(3). PMC: 7037210. DOI: 10.3390/ijms21030747. View

4.
Szilagyi J, Composto-Wahler G, Joseph L, Wang B, Rosen T, Laskin J . Anandamide down-regulates placental transporter expression through CB2 receptor-mediated inhibition of cAMP synthesis. Pharmacol Res. 2019; 141:331-342. PMC: 6391190. DOI: 10.1016/j.phrs.2019.01.002. View

5.
Malek N, Popiolek-Barczyk K, Mika J, Przewlocka B, Starowicz K . Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plast. 2015; 2015:130639. PMC: 4452105. DOI: 10.1155/2015/130639. View